Under the terms of the collaboration, AstraZeneca will evaluate a number of prostate cancer drug targets discovered by Caprion. AstraZeneca will obtain exclusive, worldwide rights to develop and commercialize therapeutic applications for its selected targets. Caprion will retain rights to all other targets for pursuit of internal or partnered product development efforts.
The terms of the agreement include an upfront payment and license fees to Caprion, as well as certain additional payments contingent upon the successful achievement of development and commercialization milestones by AstraZeneca. Specific financial terms of the agreement were not disclosed.
“Caprion’s capabilities and track record for identifying new targets in cancer is compelling,” said Dr Les Hughes, vice president and global head of cancer research for AstraZeneca. “Combined with AstraZeneca’s strong legacy of discovering and developing important new therapies for cancer, Caprion’s novel science will form an important part of our oncology efforts.”